No Data
No Data
Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Ultragenyx Pharmaceutical (RARE) and Henry Schein (HSIC)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Evolus (NASDAQ:EOLS) Is Carrying A Fair Bit Of Debt
US Manufacturing Index Rises To 43, Highest Since 2020
No Data